HPTN 071 (PopART): Rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Hayes, Richard ^a   Ayles, Helen ^a,b   Beyers, Nulda ^c   Sabapathy, Kalpana ^a   Floyd, Sian ^a   Shanaube, Kwame ^b   Bock, Peter ^c   Griffith, Sam ^d   Moore, Ayana ^d   Watson Jones, Deborah ^a   Fraser, Christophe ^e   Vermund, Sten H ^f   Fidler, Sarah ^g   Agyei, Yaw ^h   Baldwin, Megan ⁱ   Barnes, Mark ^j   Bond, Virginia ^a,k   Burns, David ^l   Chishinga, Nathaniel ^k   Cummings, Vanessa ^h   Donnell, Deborah ⁱ   Emel, Lynda ⁱ   Eshleman, Susan ^h   Godfrey Faussett, Peter ^a   Greene, Elizabeth ^m   Hargreaves, James ^a   Hauck, Katharina ⁿ   Headen, Tanette ^m   Horn, Lyn ^c   Kim, Peter ^l   Piwowar Manning, Estelle ^h   McCarthy, Katie ^l   Musheke, Maurice ^k   Mwango, Albert ^k   Mwinga, Alwyn ^k   Muyoyeta, Monde ^k   Simwinga, Musonda ^k   Schaap, Ab ^k   Smith, Peter C ⁿ   Wolf, Shauna ^h   White, Rhonda ^m   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b University of ZMB   (Zambia)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Family Health International   (United States)

^e Worldwide Clinical Trials Ltd   (United Kingdom)

^f VANDERBILT UNIVERSITY   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j Ropes and Gray LLP   (United States)

^k ZAMBART   (Zambia)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m FAMILY HEALTH INTERNATIONAL   (United States)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CIRCUMCISION, MALE; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PREVALENCE; RESEARCH DESIGN; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT; ZAMBIA;

EID: 84894076039     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-57     Document Type: Article

References (71)

1. UNAIDS Global Report: UNAIDS Report on the Global AIDS Epidemic 2012, [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf] Accessed 30 October 2013, UNAIDS.
2. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS 2010, 24(Suppl 4):S70-S80. 10.1097/01.aids.0000390709.04255.fd, 21042055.
3. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother 2011, 55(5):1831-1842. 10.1128/AAC.00976-10, 3088245, 21343462.
4. Templeton DJ. Male circumcision to reduce sexual transmission of HIV. Curr Opin HIV AIDS 2010, 5(4):344-349. 10.1097/COH.0b013e32833a46d3, 20543611.
5. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005, 2(11):e298. 10.1371/journal.pmed.0020298, 1262556, 16231970.
6. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007, 369(9562):643-656. 10.1016/S0140-6736(07)60312-2, 17321310.
7. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007, 369(9562):657-666. 10.1016/S0140-6736(07)60313-4, 17321311.
8. Johri M, Ako-Arrey D. The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc 2011, 9:3. 10.1186/1478-7547-9-3, 3045936, 21306625.
9. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007, 1:CD003510.
10. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, Martinson F, Tegha G, Knight RJ, Ahmed YI, Kamwendo DD, Hoffman IF, Ellington SR, Kacheche Z, Soko A, Wiener JB, Fiscus SA, Kazembe P, Mofolo IA, Chigwenembe M, Sichali DS, van der Horst CM. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010, 362(24):2271-2281. 10.1056/NEJMoa0911486, 3440865, 20554982.
11. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011, 11(3):171-180.
12. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010, 362(24):2282-2294. 10.1056/NEJMoa0907736, 2999916, 20554983.
13. Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011, 15(Suppl 1):S72-S79. 3064892, 21331801.
14. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, Lo YR, Souteyrand Y, Williams B. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010, 5(4):298-304. 10.1097/COH.0b013e32833a6c32, 3501989, 20543604.
15. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365(6):493-505. 10.1056/NEJMoa1105243, 3200068, 21767103.
16. Hayes R, Sabapathy K, Fidler S. Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res 2011, 9(6):429-445. 10.2174/157016211798038515, 3520051, 21999778.
17. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010, 24(5):729-735. 10.1097/QAD.0b013e32833433fe, 2852517, 20154580.
18. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373(9657):48-57. 10.1016/S0140-6736(08)61697-9, 19038438.
19. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, Montaner JS. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008, 198(1):59-67. 10.1086/588673, 18498241.
20. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?. Lancet Infect Dis 2002, 2(8):487-493. 10.1016/S1473-3099(02)00346-8, 12150848.
21. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006, 3(4):e124. 10.1371/journal.pmed.0030124, 1395349, 16519553.
22. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012, 9(7):e1001245. 10.1371/journal.pmed.1001245, 3393664, 22802730.
23. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we?. Lancet 2009, 373(9657):9-11. 10.1016/S0140-6736(08)61698-0, 19038439.
24. Wagner BG, Kahn JS, Blower S. Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?. AIDS 2010, 24(5):775-776. 10.1097/QAD.0b013e3283366782, 2895980, 20177359.
25. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009, 23(11):1397-1404. 10.1097/QAD.0b013e32832b7dca, 19381076.
26. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai. Uganda. J Infect Dis 2005, 191(9):1403-1409.
27. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146(8):591-601. 10.7326/0003-4819-146-8-200704170-00010, 17438318.
28. Gay CL, Cohen MS. Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis. Curr Infect Dis Rep 2008, 10(4):323-331. 10.1007/s11908-008-0052-5, 3567919, 18765106.
29. Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, De Pasquale MP, D'Aquila R, Caliendo AM. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010, 24(16):2489-2497. 10.1097/QAD.0b013e32833e5043, 20736815.
30. Clinical Trial.gov No NCT00867048 Strategic Timing of Antiretroviral Treatment (START) http://clinicaltrials.gov/ct2/show/NCT00867048, Clinical Trial.gov No NCT00867048.
31. De Cock KM, El-Sadr WM. When to start ART in Africa-an urgent research priority. N Engl J Med 2013, 368(10):886-889. 10.1056/NEJMp1300458, 23425131.
32. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal. South Africa. Science 2013, 339(6122):966-971.
33. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010, 15(Suppl 1):1-15.
34. Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med 2012, 9(12):e1001351. 10.1371/journal.pmed.1001351, 3514284, 23226107.
35. MacPherson P, Lalloo DG, Choko AT, Mann GH, Squire SB, Mwale D, Manda E, Makombe SD, Desmond N, Heyderman R, Corbett EL. Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre. Malawi. Trop Med Int Health 2012, 17(4):507-517.
36. Bello G, Simwaka B, Ndhlovu T, Salaniponi F, Hallett TB. Evidence for changes in behaviour leading to reductions in HIV prevalence in urban Malawi. Sex Transm Infect 2011, 87(4):296-300. 10.1136/sti.2010.043786, 3252594, 21429896.
37. Cremin I, Nyamukapa C, Sherr L, Hallett TB, Chawira G, Cauchemez S, Lopman B, Garnett GP, Gregson S. Patterns of self-reported behaviour change associated with receiving voluntary counselling and testing in a longitudinal study from Manicaland, Zimbabwe. AIDS Behav 2010, 14(3):708-715. 10.1007/s10461-009-9592-4, 2865634, 19623481.
38. Ross DA. Behavioural interventions to reduce HIV risk: what works?. AIDS 2010, 24(Suppl 4):S4-S14. 10.1097/01.aids.0000390703.35642.89, 21042051.
39. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372(9639):669-684. 10.1016/S0140-6736(08)60886-7, 2702246, 18687459.
40. Corbett EL, Makamure B, Cheung YB, Dauya E, Matambo R, Bandason T, Munyati SS, Mason PR, Butterworth AE, Hayes RJ. HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS 2007, 21(4):483-489. 10.1097/QAD.0b013e3280115402, 17301567.
41. Turner AN, Miller WC, Padian NS, Kaufman JS, Behets FM, Chipato T, Mmiro FA, Salata RA, Morrison CS. Unprotected sex following HIV testing among women in Uganda and Zimbabwe: short- and long-term comparisons with pre-test behaviour. Int J Epidemiol 2009, 38(4):997-1007. 10.1093/ije/dyp171, 2720394, 19349481.
42. NIMH Project Accept (HPTN 043) A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand http://www.hptn.org/research_studies/hptn043.asp, NIMH Project Accept (HPTN 043).
43. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One 2008, 3(5):e2212. 10.1371/journal.pone.0002212, 2387228, 18493593.
44. Lissouba P, Taljaard D, Rech D, Doyle S, Shabangu D, Nhlapo C, Otchere-Darko J, Mashigo T, Matson C, Lewis D, Billy S, Auvert B. A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. PLoS Med 2010, 7(7):e1000309. 10.1371/journal.pmed.1000309, 2907271, 20652013.
45. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 2010, 5(4):305-310. 10.1097/COH.0b013e32833a8844, 2923028, 20543605.
46. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, Ka-Gina G, Mugeye K. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995, 346(8974):530-536. 10.1016/S0140-6736(95)91380-7, 7658778.
47. Ganguli I, Bassett IV, Dong KL, Walensky RP. Home testing for HIV infection in resource-limited settings. Curr HIV/AIDS Rep 2009, 6(4):217-223.
48. UNAIDS 2011 UNAIDS World AIDS Day Report 2011, [http://www.unaidsrstesa.org/resources/reports/2011-unaids-world-aids-day-report-0] Accessed 30 October 2013, UNAIDS.
49. Wachira J, Kimaiyo S, Ndege S, Mamlin J, Braitstein P. What is the impact of home-based HIV counseling and testing on the clinical status of newly enrolled adults in a large HIV care program in Western Kenya?. Clin Infect Dis 2012, 54(2):275-281. 10.1093/cid/cir789, 22156847.
50. World Health Organization Planning, Implementation and Monitoring Home-Based HIV Counseling and Testing. A Practical Handbook for Sub-Saharan Africa 2012, [http://apps.who.int/iris/bitstream/10665/75366/1/9789241504317_eng.pdf] Accessed 30 October 2013, World Health Organization.
51. British HIV Association British HIV Association Guidelines for the Treatment of HIV-1-Positive Adults with Antiretroviral Therapy 2012, [http://www.bhiva.org/documents/Guidelines/Treatment/2012/hiv1029_2.pdf] Accessed 30 October 2013, British HIV Association.
52. European AIDS Clinical Society European AIDS Clinical Society Guidelines 2013, http://eacsociety.org/Portals/0/Guidelines_Online_131014.pdf Accessed 30 October 2013, European AIDS Clinical Society.
53. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected for Adults and Adolescents 2011, [http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf] Accessed 30 October 2013, Panel on Antiretroviral Guidelines for Adults and Adolescents.
54. World Health Organization Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach (2010 version) 2010, [http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf] Accessed 30 October 2013, World Health Organization.
55. HPTN 071 (PopART) Protocol Team HPTN 071 Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-Randomized Trial of the Impact of a Combination Prevention Package on Population-Level HIV Incidence in ZMB and South Africa 2012, [http://www.hptn.org/research_studies/hptn071.asp] Accessed 30 October 2013, HPTN 071 (PopART) Protocol Team.
56. National AIDS Council Z ZMB Country Report. Monitoring the Declaration of Commitment on HIV and AIDS and the Universal Access 2012, [http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_ZM_Narrative_Report.pdf] Accessed 30 October 2013, National AIDS Council Z.
57. South African National AIDS Council Global Aids Response Progress Report 2012, South Africa 2012, [http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_ZA_Narrative_Report.pdf] Accessed 30 October 2013, South African National AIDS Council.
58. Ayles HM, Sismanidis C, Beyers N, Hayes RJ, Godfrey-Faussett P. ZAMSTAR, The ZMB South Africa TB and HIV Reduction Study: design of a 2 x 2 factorial community randomized trial. Trials 2008, 9:63. 10.1186/1745-6215-9-63, 2585552, 18992133.
59. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010, 5(6):e11068. 10.1371/journal.pone.0011068, 2883572, 20548786.
60. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J, Lingappa JR, Celum C. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375(9731):2092-2098. 10.1016/S0140-6736(10)60705-2, 2922041, 20537376.
61. Obasi A, Mosha F, Quigley M, Sekirassa Z, Gibbs T, Munguti K, Todd J, Grosskurth H, Mayaud P, Changalucha J, Brown D, Mabey D, Hayes R. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis 1999, 179(1):16-24. 10.1086/314555, 9841817.
62. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994, 309(6965):1325-1329. 10.1136/bmj.309.6965.1325, 2541869, 7866079.
63. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990, 69:19-36.
64. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, Eaton JW, Hauck K, Smith P, Griffith S, Moore A, Donnell D, Vermund SH, Fidler S, Hayes R, Fraser C, team Hs HPTN 071 (PopART): A Cluster-Randomized Trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One 2014, 9(1):e84511. 10.1371/journal.pone.0084511, 3893126, 24454728, team Hs.
65. Bennett S, Parpia T, Hayes R, Cousens S. Methods for the analysis of incidence rates in cluster randomized trials. Int J Epidemiol 2002, 31(4):839-846. 10.1093/ije/31.4.839, 12177032.
66. Hayes RJ, Alexander ND, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Med Res 2000, 9(2):95-116. 10.1191/096228000670953670, 10946429.
67. Hayes RJ, Moulton LH. Cluster Randomised Trials 2009, Boca Raton: Chapman and Hall.
68. World Health Organization Consultation on Antiretroviral Treatment for Prevention of HIV Transmission Meeting report 2009, [http://www.who.int/hiv/topics/artforprevention/Artmeetingreport.pdf] Accessed 30 October 2013, World Health Organization.
69. ANRS 12249 TasP Trial Team Impact of Immediate Versus WHO Recommendations Guided ART Initiation on HIV Incidence - Feasibility Phase (TasP). [http://clinicaltrials.gov/ct2/show/NCT01509508] Accessed 30 October 2013, ANRS 12249 TasP Trial Team.
70. Botswana Combination Prevention Study Group Botswana Combination Prevention Project (BCPP) 2012, [http://clinicaltrials.gov/ct2/show/NCT01965470] Accessed 30 October 2013, Botswana Combination Prevention Study Group.
71. Vermund SH, Hayes RJ. Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep 2013, 10(2):169-186.